UBISOFT Entertainment header image

UBISOFT Entertainment

UBI

Equity

ISIN FR0000054470 / Valor 491199

Euronext - Euronext Paris (2025-11-18)
EUR 6.77%

UBISOFT Entertainment
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Ubisoft Entertainment is a multinational company engaged in the creation, development, and publishing of video games. It operates a network of studios worldwide, with a workforce of approximately 17,000 employees, and focuses on both developing original titles and licensing high-profile games. Recently, the company secured cloud streaming rights for a major slate of games—including titles like Call of Duty—through an agreement contingent on the completion of Microsoft’s acquisition of Activision Blizzard, positioning these titles on its Ubisoft+ service as well as through licensing to other digital gaming platforms. Additionally, Ubisoft invests in technological tools that enhance accessibility in gaming, such as its open-source colorblind simulation software, supporting developers in creating more inclusive content.

Summarized from source with an LLMView SourceSector: Technology

Latest Results (13.10.2025):

Ubisoft Entertainment reported its full-year financial results for FY2024-25, achieving overall performance broadly in line with targets. Despite facing challenges such as lower than expected net bookings due to timing impacts in partnerships, the company delivered a solid free cash flow of €128 million, surpassing its objectives. The successful launch of Assassin’s Creed® Shadows and ongoing transformation initiatives underscore Ubisoft's commitment to enhancing its brand strength and operational efficiency.

Net Bookings Slightly Below Target

For FY2024-25, Ubisoft Entertainment reported net bookings of €1.85 billion, which is slightly below the objective by 17.5%. This shortfall was primarily driven by lower than expected partnerships, reflecting a timing impact. Digital net bookings accounted for 85.6% of total net bookings, while PRI net bookings and back-catalog net bookings stood at €806.1 million and €1,296.3 million respectively.

Strong Free Cash Flow

The company achieved a free cash flow of €128 million, exceeding its target. This was driven by cash flow from operating activities amounting to €169 million. Non-IFRS operating income was in line with guidance, demonstrating effective financial management despite the challenges faced during the fiscal year.

Successful Game Launch: Assassin’s Creed® Shadows

The release of Assassin’s Creed® Shadows was a highlight of the fiscal year, receiving strong praise from players and achieving the second-highest Day 1 sales revenue in the franchise's history. The game has generated over 160 million player hours, reinforcing the strength of the Assassin’s Creed brand and contributing positively to Ubisoft's financial performance.

Ongoing Transformation and Cost Reduction

Ubisoft has made significant progress in its transformation efforts, including the completion of its initial cost savings program ahead of schedule, achieving over €200 million in savings. The company plans to implement an additional fixed cost reduction of at least €100 million over the next two years. Moreover, a new Group organization is set to be announced by the end of the year to better serve player needs and enhance operational efficiency.

Positive Outlook for Future Growth

Looking ahead, Ubisoft projects net bookings to remain stable in FY2025-26, with a target of approximately breakeven non-IFRS operating income and a negative free cash flow as the group continues its transformation. The company expects to return to positive operating income and free cash flow generation in FY2026-27, supported by significant content releases from its largest brands and the successful integration of its new subsidiary backed by Tencent.

Summarized from source with an LLMView Source

Key figures

-49.1%1Y
-73.9%3Y
-91.7%5Y

Performance

52.1%1Y
50.0%3Y
46.9%5Y

Volatility

Market cap

1025 M

Market cap (USD)

Daily traded volume (Shares)

Daily traded volume (Shares)

1 day high/low

13 / 12.735

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc Zentalis Pharmaceuticals Inc Valor: 53183848
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.03%USD 1.36
Shopify Inc
Shopify Inc Shopify Inc Valor: 27926256
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.29%CAD 196.32
Open Text Corp
Open Text Corp Open Text Corp Valor: 241964
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.06%CAD 46.15
CAE Inc
CAE Inc CAE Inc Valor: 680472
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.99%CAD 36.01
Duolingo Inc
Duolingo Inc Duolingo Inc Valor: 112404331
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.58%USD 175.45
HubSpot Inc
HubSpot Inc HubSpot Inc Valor: 25302411
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.21%USD 368.33
Palantir Technologies Inc
Palantir Technologies Inc Palantir Technologies Inc Valor: 36244719
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.29%USD 167.33
Texas Instruments Inc
Texas Instruments Inc Texas Instruments Inc Valor: 976910
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.50%USD 157.32
Booking Holdings Inc
Booking Holdings Inc Booking Holdings Inc Valor: 40656108
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.44%USD 4,783.01
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc Regeneron Pharmaceuticals Inc Valor: 965755
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.99%USD 725.34